This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sekar, V. J.
Right arrow Articles by Hoetelmans, R. M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sekar, V. J.
Right arrow Articles by Hoetelmans, R. M. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 958-961, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01203-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pharmacokinetic Interaction between Darunavir Boosted with Ritonavir and Omeprazole or Ranitidine in Human Immunodeficiency Virus-Negative Healthy Volunteers{triangledown}

Vanitha J. Sekar,1* Eric Lefebvre,1 Els De Paepe,2 Tine De Marez,1 Martine De Pauw,2 Wim Parys,1 and Richard M. W. Hoetelmans2

Tibotec Inc., Yardley, Pennsylvania,1 Tibotec BVBA, Mechelen, Belgium2

Received 25 September 2006/ Returned for modification 12 November 2006/ Accepted 22 December 2006

Darunavir (DRV; TMC114; Prezista) is a human immunodeficiency virus (HIV) protease inhibitor used in combination with low-dose ritonavir (RTV) (DRV/r) as a pharmacokinetic enhancer. Protease inhibitor absorption may be decreased during coadministration of drugs that limit stomach acid secretion and increase gastric pH. This study was conducted to investigate the effect of ranitidine and omeprazole on the plasma pharmacokinetics of DRV and RTV in HIV-negative healthy volunteers. Sixteen volunteers completed the study and received DRV/r, DRV/r plus ranitidine, and DRV/r plus omeprazole, in three separate sessions. Treatment was given for 4 days with an additional morning dose on day 5, and regimens were separated by a washout period of 7 days. Samples were taken over a 12-h period on day 5 for the assessment of DRV and RTV plasma concentrations. Pharmacokinetic parameters assessed included DRV area under the curve, maximum plasma concentration, and trough plasma concentration. The least-squares mean ratios and 90% confidence intervals are reported with treatment of DRV/r alone as a reference. Compared with DRV/r alone, no significant changes in DRV pharmacokinetic parameters were observed during coadministration of DRV/r and either ranitidine or omeprazole. Treatment regimens were generally well tolerated, and no serious adverse events were reported. In conclusion, coadministration of DRV/r and ranitidine or omeprazole was well tolerated by the volunteers. Ranitidine and omeprazole did not have a significant influence on DRV pharmacokinetics. No dose adjustments are required when DRV/r is coadministered with omeprazole or ranitidine.

* Corresponding author. Mailing address: Tibotec Inc., 1020 Stony Hill Road, Suite 300, Yardley, PA 19067. Phone: (609) 730-7500. Fax: (609) 730-7501. E-mail: VSekar{at}tibus.jnj.com.

{triangledown} Published ahead of print on 8 January 2007.

Antimicrobial Agents and Chemotherapy, March 2007, p. 958-961, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01203-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Luber, A. D. (2008). Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2008: More Than It Seems?. J Int Assoc Physicians AIDS Care (Chic Ill) 7: 10-16 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»